AzTrials
AzTrials

EGCG Influence on Catecholamine MetabolismPhase 4NCT03199430

Epigallocatechin Gallate Lowers Circulating Catecholamine Concentrations and Alters Lipid Metabolism.

A Phase 4 study testing Epigallocatechin gallate in people with EGCG Influence on Catecholamine Metabolism, run by Swansea University.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study was to explore the impact of acute ingestion of the polyphenol epigallocatechin galate (EGCG) on catecholamine, catecholamine metabolite, systemic metabolic and cardio-vascular variables across a range of exercise intensities during graded cycle exercise in man. Read more about this study

Who is it for?
Ages 18 to 35 years, men onlyHealthy volunteers can take part
What is being tested?
Epigallocatechin gallate
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
8 participants
Where
No sites listed yet
Study dates
Sep 2015to Feb 2016
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Age 18-35 years old. Caffeine intake ≤400 mg.d-1 (thus less than four cups of tea/ coffee or caffeinated soda beverages).
  • Habitual participation in exercise three to five times per week for 30-90 minutes per formal exercise session.

Who cannot join

  • Female Any injury, assessed via health screening questionnaire prior to the start of the study.

About this study

Official title: The Polyphenol Epigallocatechin Gallate Lowers Circulating Catecholamine Concentrations and Alters Lipid Metabolism During Graded Exercise in Man.

The aim of this study was to explore the impact of acute ingestion of the polyphenol epigallocatechin galate (EGCG) on catecholamine, catecholamine metabolite, systemic metabolic and cardio-vascular variables across a range of exercise intensities during graded cycle exercise in man.

Read the detailed description

Written informed consent was obtained from all subjects and all subjects completed the AHA/ACSM health screening questionnaire to ascertain their health status and to show their eligibility to partake in this study.

In a randomized, placebo-controlled, single blind, cross-over design study participants completed two trials after acute consumption of either EGCG or a placebo (PLAC) supplement after an overnight fast. After a two-hour monitoring period following ingestion participants performed a continuous graded cycle exercise test to volitional exhaustion. There was at least a 7-day washout period between trials.

Participants were randomly assigned to either the intervention or placebo trial. After an overnight fast participants arrived to the laboratory and were observed ingesting two capsules each of EGCG (minimum 94% EGCG <0.1% caffeine) from a commercially available brand (TEAVIGO™; TAIYO GmbH, 1450 mg) or a placebo (1450 mg Corn Flour). Capsules were weighed and sorted to within ±5%. The supplement was consumed in two size 00 vegetarian gelatin capsules alongside a standardized amount of distilled water (200ml).

Experimental Protocol Prior to participation in the experimental trials participants were familiarized with the laboratory equipment and the test procedures. On the morning of the test participants reported to the Exercise Physiology Laboratory following an 8-10 hour fast where standard measures of the participants' body mass, (weighting scales; Seca 770 Digital Scales, Seca Ltd, Birmingham, UK) height (stadiometer; Holtain Stadiometer, Holtain Ltd, Cymrych, Wales) and body fat percentage using bioelectrical impedance analysis (Bodystat Quadscan 4000, Bodystat Ltd, Isle of Man, UK) whilst wearing minimal clothing, were taken.

Participants were then seated for a 10-minute period while a cannula was inserted into an antecubital vein. This was connected to a three-way stopcock for the repeated collection of venous blood at rest and during the exercise test. Saline (2-3 ml) was infused regularly keep the cannula patent. After a 10-minute rest period a venous blood sample (7 ml) was collected into a lithium-heparinised vacutainer. In addition, baseline measures of heart rate (Polar RS800CX), and a 10-minute sample of respiratory gas (Jaeger Vyuntus CPX, Erich Jaeger GmbH,CareFusion Hoechbegh, Germany) were also taken at this time. Expired air was measured for the fractional concentration of oxygen (FEO2%) and carbon dioxide (FECO2%) and for the volume of air (SentrySuite Software, Erich Jaeger GmbH,CareFusion Hoechbegh, Germany) expired during the period to allow for determination of volumes of O2 utilization and CO2 production. These data were used for determination of oxidative energy expenditure using principles of indirect calorimetry (Frayn 1983; Jeukendrup \& Wallis, 2005).

Following collection of resting parameters participants were rested in a semi-reclined position for two hours. Thereafter, after a 5-minute transition period, participants mounted a cycle ergometer (Lode Excalibur Sport Ergometer, Lode BV Groningen, The Netherlands) to perform a graded exercise test. Participants were instructed to cycle between 60-70 rpm at an initial power output of 60 Watts (W) with an increase in 30 W every 3 minutes. Verbal encouragement was provided to the participant throughout. Heart rate was measured constantly throughout the exercise test in real-time via a telemetry chest strap and wireless receiver (Polar RS800CX) alongside respiratory gas measurements. Two and a half minutes into each stage, a rating of perceived exertion (RPE) was taken from the participant (Borg, 1982) and a venous blood sample taken. The test continued until volitional exhaustion which was defined by the following criteria 1) cadence dropping below 50 rpm, 2) heart rate within 10 beats of age-predicted maximum, 3) levelling off of VO2 though workload had increased. At this point cardio-respiratory variables were recorded and a final blood sample was taken at exhaustion.

Participants were given a food and physical activity diaries to complete in the 72 hours prior to the first experimental trial. Participants were also instructed to avoid alcohol, foods with high polyphenols content and additional green tea consumption during this period. Participants were also instructed not to perform any physical activity in the 24h period immediately prior to the exercise trial.

Blood Analyses Venous blood samples were analysed immediately for lactate and glucose levels (Biosen C-Line, EKF Diagnostics). Thereafter, the remainder of the sample was centrifuged (Heraeus Megafuge 8, Thermo Scientific) for 10 minutes at 3,000 rpm) with ~3ml of plasma extracted into individual 1ml microcentrifuge tubes and frozen immediately (-80°C) for later analysis of metanephrine, normetanephrine and catecholamine (adrenaline and noradrenaline) concentrations using commercially available enzyme linked absorbent assays (ELISA, Eagle Biosciences Inc, Nashua, New Hampshire, USA). Blood points selected for use with the assay kits were, baseline (REST), two hours post ingestion at rest (POST-ING) and during exercise at highest lipid oxidation rate (FATpeak), lactate threshold (LT) and at peak rate of oxygen consumption (VO2peak) for each individual were analysed. Lactate threshold was calculated using Lactate-E software (Newell et al, 2007).

The data was analysed using the Statistical Package for the Social Sciences software (Version 22, SPSS, inc). Data was reported as means±SD with P0.05 accepted. All variables were examined using paired t-tests for comparison of experimental trial differences.

Being tested
Epigallocatechin gallate, Placebo
Keywords
catecholamines, Exercise, lipid metabolism
Medical subject headings
Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Epigallocatechin gallateDietary supplement

  • PlaceboDietary supplement

    1450mg Corn Flour

Study groups in NCT03199430
Study groupRoleWhat they receive
PlaceboPlacebo comparator1450mg Corn flour
Receives: Dietary Supplement: Placebo
Epigallocatechin gallateActive comparator1450mg Epigallocatechin gallate
Receives: Dietary Supplement: Epigallocatechin gallate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. change in Adrenaline & Noradrenaline concentrations (nmol.l-1)

    Changes in Adrenaline \& Noradrenaline concentrations (nmol.l-1) from rest to exhaustion under EGCG and placebo conditions.

    Measured: Relativised to each metabolic domain; rest, 2 hours post ingestion, highest lipid oxidation rate during exercise, lactate threshold and VO2peak (participant dependant)

  2. Changes in Metanephrine and Normetanephrine (pmol.l-1)

    Changes in Metanephrine \& Normetanephrine concentrations (pmol.l-1) from rest to exhaustion under EGCG and placebo conditions.

    Measured: Relativised to each metabolic domain; rest, 2 hours post ingestion, highest lipid oxidation rate during exercise, lactate threshold and VO2peak (participant dependant)

  3. Changes in lipid and carbohydrate oxidation (g.min-1)

    Changes in lipid and carbohydrate oxidation (g.min-1) from rest to exhaustion under EGCG and placebo conditions.

    Measured: Over a period of approximately 2 and a half hours with the data collected relativised to each metabolic domain; rest, highest lipid oxidation rate during exercise, lactate threshold and VO2peak (participant dependant)

Secondary outcomes (4)
  1. Changes in blood glucose concentrations (mmol.l-1)

    Changes in glucose concentrations (pmol.l-1) from rest to exhaustion under EGCG and placebo conditions.

    Measured: Relativised to each metabolic domain; rest, two hours post ingestion, highest lipid oxidation rate during exercise, lactate threshold and VO2peak (participant dependant)

  2. Changes in exercise performance (S) under EGCG and placebo conditions.

    Changes in markers of exercise performance, (performance time) under EGCG and placebo conditions

    Measured: over a period of approximately 30 minutes from rest to volitional exhaustion.

  3. Changes in blood lactate concentrations (mmol.l-1)

    Changes in lactate concentrations (pmol.l-1) from rest to exhaustion under EGCG and placebo conditions.

    Measured: Relativised to each metabolic domain; rest, two hours post ingestion, highest lipid oxidation rate during exercise, lactate threshold and VO2peak (participant dependant)

  4. Changes in exercise performance (W) under EGCG and placebo conditions.

    Changes in markers of exercise performance, (maximal power obtained) under EGCG and placebo conditions

    Measured: over a period of approximately 30 minutes from rest to volitional exhaustion.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jun 2017
  2. Study startSep 2015
  3. Primary completionJan 2016
  4. Study completionFeb 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Participant
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03199430
Sponsor's protocol ID
PG/2014/28
Status last verified
Jun 2017
First submitted
3 Aug 2016
Last updated
27 Jun 2017
Results posted
No
Data monitoring committee
No

Publications

  • Newell J, Higgins D, Madden N, Cruickshank J, Einbeck J, McMillan K, McDonald R. Software for calculating blood lactate endurance markers. J Sports Sci. 2007 Oct;25(12):1403-9. doi: 10.1080/02640410601128922.

    PubMed 17786693
  • Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol Respir Environ Exerc Physiol. 1983 Aug;55(2):628-34. doi: 10.1152/jappl.1983.55.2.628.

    PubMed 6618956
  • Jeukendrup AE, Wallis GA. Measurement of substrate oxidation during exercise by means of gas exchange measurements. Int J Sports Med. 2005 Feb;26 Suppl 1:S28-37. doi: 10.1055/s-2004-830512.

    PubMed 15702454

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Epigallocatechin gallate in people with EGCG Influence on Catecholamine Metabolism, run by Swansea University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

change in Adrenaline & Noradrenaline concentrations (nmol.l-1) (time frame: Relativised to each metabolic domain; rest, 2 hours post ingestion, highest lipid oxidation rate during exercise, lactate threshold and VO2peak (participant dependant)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03199430, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in